Patents by Inventor Thiwanka Samarakoon

Thiwanka Samarakoon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210299269
    Abstract: Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein. In an embodiment, the splicing modulator comprises a pladienolide or a pladienolide derivative.
    Type: Application
    Filed: May 31, 2019
    Publication date: September 30, 2021
    Inventors: Ermira PAZOLLI, Silvia BUONAMICI, Thiwanka SAMARAKOON, Sudeep PRAJAPATI, Nathan FISHKIN, James PALACINO, Michael SEILER, Ping ZHU, Andrew COOK, Peter SMITH, Xiang LIU, Shelby ELLERY, Dominic REYNOLDS, Lihua YU, Zhenhua WU, Shouyong PENG, Nicholas CALANDRA, Megan SHEEHAN, Yonghong Xiao
  • Publication number: 20210177837
    Abstract: The present disclosure provides pladienolide compounds, pharmaceutical compositions containing such compounds, and pladienolide compounds for use in methods of medical treatment. These compounds may be useful in the treatment of cancer, particularly cancers in which agents that target the spliceosome and mutations therein are known to be useful. Also provided herein are pladienolide compounds for use in methods of treating cancers by administering at least one pladienolide compound disclosed herein and at least one additional therapy.
    Type: Application
    Filed: April 11, 2019
    Publication date: June 17, 2021
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Andrew COOK, Dominic REYNOLDS, Cheng ZHONG, Ryan BRAWN, Shelby ELLERY, Thiwanka SAMARAKOON, Xiang LIU, Sudeep PRAJAPATI, Megan SHEEHAN, Jason T. LOWE, James PALACINO
  • Publication number: 20210101888
    Abstract: Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein. In an embodiment, the splicing modulator comprises a pladienolide or a pladienolide derivative.
    Type: Application
    Filed: November 30, 2020
    Publication date: April 8, 2021
    Inventors: Ermira PAZOLLI, Silvia BUONAMICI, Thiwanka SAMARAKOON, Sudeep PRAJAPATI, Nathan FISHKIN, James PALACINO, Michael SEILER, Ping ZHU, Andrew COOK, Peter SMITH, Xiang LIU, Shelby ELLERY, Dominic REYNOLDS, Lihua YU, Zhenhua WU, Shouyong PENG, Nicholas CALANDRA, Megan SHEEHAN, Yonghong XIAO
  • Publication number: 20200255415
    Abstract: Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-? protein.
    Type: Application
    Filed: November 22, 2017
    Publication date: August 13, 2020
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Mark Bock, Ming-Hong Hao, Manav Korpal, Vijay Kumar Nyavanandi, Xiaoling Puyang, Susanta Samajdar, Peter Gerard Smith, John Wang, Guo Zhu Zheng, Ping Zhu, Lorna Helen Mitchell, Nicholas Larsen, Nathalie Rioux, Sudeep Prajapati, Dominic Reynolds, Morgan O'Shea, Thiwanka Samarakoon
  • Publication number: 20180141913
    Abstract: Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-? protein.
    Type: Application
    Filed: November 22, 2017
    Publication date: May 24, 2018
    Applicant: EISAI R & D MANAGEMENT CO., LTD.
    Inventors: Mark BOCK, Ming-Hong HAO, Manav KORPAL, Vijay Kumar NYAVANANDI, Xiaoling PUYANG, Susanta SAMAJDAR, Peter Gerard SMITH, John WANG, Guo Zhu ZHENG, Ping ZHU, Lorna Helen MITCHELL, Nicholas LARSEN, Nathalie RIOUX, Sudeep PRAJAPATI, Dominic REYNOLDS, Morgan O'SHEA, Thiwanka SAMARAKOON
  • Patent number: 9382228
    Abstract: Described are compounds of Formula I which find utility in the treatment of cancer, autoimmune diseases and metabolic bone disorders through inhibition of c-FMS (CSF-1R), c-KIT, and/or PDGFR kinases. These compounds also find utility in the treatment of other mammalian diseases mediated by c-FMS, c-KIT, or PDGFR kinases.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: July 5, 2016
    Assignee: Deciphera Pharmaceuticals, LLC
    Inventors: Daniel L. Flynn, Timothy Malcolm Caldwell, Michael D. Kaufman, William C. Patt, Thiwanka Samarakoon, Lakshminarayana Vogeti, Karen M. Yates
  • Patent number: 9309224
    Abstract: Described are compounds of Formula 1 which find utility in the treatment of cancer, autoimmune diseases and metabolic bone disorders through inhibition of c-FMS (CSF-1R), c-KIT, and/or PDGFR kinases. These compounds also find utility in the treatment of other mammalian diseases mediated by c-FMS, c-KIT, or PDGFR kinases.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: April 12, 2016
    Assignee: Deciphera Pharmaceuticals, LLC.
    Inventors: Daniel L. Flynn, Timothy Malcolm Caldwell, Thiwanka Samarakoon, Lakshminarayana Vogeti, Michael D. Kaufman, William C. Patt, YuMi Ahn
  • Publication number: 20160046619
    Abstract: Described are compounds of Formula I which find utility in the treatment of cancer, autoimmune diseases and metabolic bone disorders through inhibition of c-FMS (CSF-1R), c-KIT, and/or PDGFR kinases. These compounds also find utility in the treatment of other mammalian diseases mediated by c-FMS, c-KIT, or PDGFR kinases.
    Type: Application
    Filed: August 3, 2015
    Publication date: February 18, 2016
    Inventors: Daniel L. Flynn, Michael D. Kaufman, Thiwanka Samarakoon, Timothy Malcolm Caldwell, Lakshminarayana Vogeti, YuMi Ahn, William C. Patt, Karen M. Yates
  • Patent number: 9193719
    Abstract: Described are compounds of Formula I which find utility in the treatment of cancer, autoimmune diseases and metabolic bone disorders through inhibition of c-FMS (CSF-1R), c-KIT, and/or PDGFR kinases. These compounds also find utility in the treatment of other mammalian diseases mediated by c-FMS, c-KIT, or PDGFR kinases.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: November 24, 2015
    Assignee: Deciphera Pharmaceuticals, LLC
    Inventors: Daniel L. Flynn, Gary E. L. Brandt, Michael D. Kaufman, Hanumaiah Telikepalli, Timothy Malcolm Caldwell, Thiwanka Samarakoon
  • Patent number: 9133183
    Abstract: Described are compounds of Formula I which find utility in the treatment of cancer, autoimmune diseases and metabolic bone disorders through inhibition of c-FMS (CSF-1R), c-KIT, and/or PDGFR kinases. These compounds also find utility in the treatment of other mammalian diseases mediated by c-FMS, c-KIT, or PDGFR kinases.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: September 15, 2015
    Assignee: Deciphera Pharmaceuticals, LLC
    Inventors: Daniel L. Flynn, Michael D. Kaufman, Thiwanka Samarakoon, Timothy Malcolm Caldwell, Lakshminarayana Vogeti, YuMi Ahn, William C. Patt, Karen M. Yates
  • Publication number: 20140315917
    Abstract: Described are compounds of Formula I which find utility in the treatment of cancer, autoimmune diseases and metabolic bone disorders through inhibition of c-FMS (CSF-1R), c-KIT, and/or PDGFR kinases. These compounds also find utility in the treatment of other mammalian diseases mediated by c-FMS, c-KIT, or PDGFR kinases.
    Type: Application
    Filed: March 14, 2014
    Publication date: October 23, 2014
    Applicant: Deciphera Pharmaceuticals, LLC
    Inventors: Daniel L. Flynn, Michael D. Kaufman, Thiwanka Samarakoon, Timothy Malcolm Caldwell, Lakshminarayana Vogeti, YuMi Ahn, William C. Patt, Karen M. Yates
  • Publication number: 20140296252
    Abstract: Described are compounds of Formula I which find utility in the treatment of cancer, autoimmune diseases and metabolic bone disorders through inhibition of c-FMS (CSF-1R), c-KIT, and/or PDGFR kinases. These compounds also find utility in the treatment of other mammalian diseases mediated by c-FMS, c-KIT, or PDGFR kinases.
    Type: Application
    Filed: March 14, 2014
    Publication date: October 2, 2014
    Applicant: Deciphera Pharmaceuticals, LLC
    Inventors: Daniel L. Flynn, Gary E. L. Brandt, Michael D. Kaufman, Hanumaiah Telikepalli, Timothy Malcolm Caldwell, Thiwanka Samarakoon
  • Publication number: 20140275080
    Abstract: Described are compounds of Formula I which find utility in the treatment of cancer, autoimmune diseases and metabolic bone disorders through inhibition of c-FMS (CSF-1R), c-KIT, and/or PDGFR kinases. These compounds also find utility in the treatment of other mammalian diseases mediated by c-FMS, c-KIT, or PDGFR kinases.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Applicant: Deciphera Pharmaceuticals, LLC
    Inventors: Daniel L. Flynn, Timothy Malcolm Caldwell, Michael D. Kaufman, William C. Patt, Thiwanka Samarakoon, Lakshminarayana Vogeti, Karen M. Yates
  • Publication number: 20140275016
    Abstract: Described are compounds of Formula 1 which find utility in the treatment of cancer, autoimmune diseases and metabolic bone disorders through inhibition of c-FMS (CSF-1R), c-KIT, and/or PDGFR kinases. These compounds also find utility in the treatment of other mammalian diseases mediated by c-FMS, c-KIT, or PDGFR kinases.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Applicant: Deciphera Pharmaceuticals, LLC
    Inventors: Daniel L. Flynn, Timothy Malcolm Caldwell, Thiwanka Samarakoon, Lakshminarayana Vogeti, Michael D. Kaufman, William C. Patt, YuMi Ahn